Generation of a retroviral vector that expresses an anti-HIV-1 tat
hammerhead ribozyme
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Ribozymes have emerged as promising therapeutics for HIV and have been shown to bind and cleave target RNA’s in a
sequence-specific manner. The HIV-1 regulatory protein tat plays an essential role in the upregulation of viral transcription and
elongation of viral transcripts, and has therefore been identified as a target for ribozyme studies. To further study the use of
these reagents, we have designed a number of hammerhead ribozymes targeted to specific sequences within the HIV-1 NL43 tat
sequence. One of these, Tat5910 and its non-catalytic control Tat5910∆, were cloned into the retroviral vector
pSuper.retro.neo+GFP (pSRNG) for cell culture studies. Recombinant retrovirus particles were generated by transient
transfection of 293T cells using a two-plasmid system consisting of the helper plasmid, pPAM3, and pSRNG5910∆. Identical
experiments were carried out using two Mo-MLV retroviral vectors, pLNCE, and pLNCLZRz. The resulting recombinant virus
was used to transduce NIH-3T3 cells, and virus titer (virus particles/ml) was determined from the number of Green Fluorescent
Protein (GFP)- or β-galactosidase-positive cells. Although producer cells transfected with pSRNG5910∆ expressed GFP, the
transfection efficieny was low. This resulted in levels of transduced NIH-3T3 cells that were too low to obtain a reliable titer
measurement. Attempts to optimize titer by increasing the number of transfected producer 293T cells was successful using
pLNCE and pLNCLZRz. Positive GFP or β-galactosidase expression in NIH-3T3 cells transduced with LNCE and LNCLzRz
recombinant virus indicated that our two-plasmid virus production system was successful. Extremely low titer along with lower
cellular expression of GFP suggests that the pSRNG5910 vectors may be better suited to virus production using a stable
producer cell line such as PA317

Introduction
Human Immunodeficiency Virus (HIV-1) infection
results in the gradual loss of T H cells, decreased immune
competence, and increased susceptibility to various opportunistic
infections, including Pneumocystis jirovecii pneumonia,
tuberculosis, and cytomegalovirus. Infection by these
opportunistic infections, in addition to a T H lymphocyte count
below 200/mm3, define the Acquired Immune Deficiency
Syndrome (AIDS) (1).
Traditional HIV treatments have sought to reduce viral
load by utilizing drugs that prohibit effective viral replication (2).
For example, Triple Combination Therapy (TCT), which involves
one protease inhibitor and two reverse transcriptase (RT)
inhibitors, has been shown to effectively reduce viral load (2).
Nevertheless, resistance to protease and RT inhibitors have
already developed, requiring a continued search for therapies that
can inhibit other HIV gene functions (3). For HIV, these
functions are generally associated with the six accessory genes
that control infection and replication: tat, rev, nef,vif, vpr, and vpu
(4).
Tat increases viral transcription from the HIV-1 Long
Terminal Repeat (LTR) by binding to the cis acting RNA
enhancer element, the transactivation response region (TAR),
which is transcribed from the R (Repeat) region of the 5’ LTR
(5). Once transcribed, TAR forms a hairpin loop consisting of a
base-paired stem, a three nucleotide non-base-paired bulge, and a
six-nucleotide Guanine-rich loop (2) that is present at the 5’ end
of all viral transcripts. The Tat/TAR interaction recruits
numerous cellular transcriptional coactivators to TAR, including
P-TEFb (Positive Transcription Elongation Factor b), an RNA

polymerase II C-terminal kinase, resulting in the phosphorylation
of the C-Terminal Domain (CTD) of RNA Polymerase II (6). The
phosphorylation of the CTD increases RNA polymerase II
processivity, thereby inducing elongation of viral transcripts (7).
Tat is absolutely required for HIV replication and is, therefore, an
important target for novel anti-HIV reagents.
Targeting HIV-1 at the genomic level can be
accomplished by hammerhead ribozymes, which are small
catalytic RNAs that can be targeted to cleave viral mRNAs (8).
These RNA enzymes target and cleave mRNA at any XUX’,
where X is any nucleotide, and X’ is Adenine, Cytosine, or Uracil
(8). Hammerhead ribozyme design, based on the Hasseloff and
Gerlach model (9), consists of two flanking regions that provide
target specificity by Watson-Crick base pairing and a catalytic
core that cleaves at the target site. Cleavage of tat mRNA
sequences by hammerhead ribozymes may negatively impact
transcription initiation and elongation, leading to the inability of
HIV to replicate within cells (10;11).
Previously, our lab designed and cloned a number of
hammerhead ribozymes targeted to the tat genomic sequence of
the HIV-1 genomic clone NL43. Each of these ribozymes and a
corresponding non-catalytic control ribozyme was cloned into the
shuttle vector, pPCR-Script. For initial cell culture testing,
Tat5910 and its non-catalytic control Tat5910∆, were subcloned
into the retroviral vector pSuper.Retro.Neo+GFP (pSRNG). This
modified Moloney Murine Leukemia virus (Mo-MLV) vector can
infect non-dividing cells (e.g., hematopoietic stem cells) and is
self-inactivating due to a deletion in the 3’ LTR (12). Importantly
this vector has been designed to express siRNAs from the RNA
Polymerase III H1 promoter (13), making it a logical choice for
expressing other small RNAs such as hammerhead ribozymes.
For selection purposes pSRNG expresses neomycin
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phosphotransferase and green fluorescent protein (GFP) from a
single IRES-containing transcript controlled by the
phosphoglycerokinase (PGK) promoter (13).
This paper describes cloning of an anti-HIV
hammerhead ribozyme Tat5910 into the retroviral vector,
pSuper.retro.neo+GFP, along with initial cell culture testing.
These tests involved analysis of transgene expression and
optimizing virus titer produced in a transient producer cell
system. For this we utilized a two-plasmid system consisting of a
retroviral vector and a helper plasmid (14).

Figure 1. Hammerhead ribozyme design. Tat RNA showing the pGUA
cleavage site at nucleotide 5910 is shown annealed to the ribozyme
flanking regions. The catalytic core was made inactive by an A to G
mutation (11).

Materials and Methods
Oligonucleotides and cloning
A hammerhead ribozyme, based on the Haseloff and
Gerlach model (9) was designed to cleave a pGUA sequence at
nucleotide 5910 within the HIV genomic clone NL43 (Accession
number M19921) (Figure 1). The Tat5910 sense (5’-gat ccA
AGC AAC ACT TTT CTG ATG AGT CCG TGA GGA CGA
AAC AAT AGC AAT TGG TAC Aa- 3’) and antisense
sequences (5’-agc ttT GTA CCA ATT GCT ATT GTT TCG
TCC TCA CGG ACT CAT CAG AAA AGT GTT GCT Tg- 3’)
were synthesized with BamHI and HindIII sites to facilitate
cloning. Two-hundred picomoles of each oligonucleotide were
combined in annealing buffer (100mM NaCl, 50mM HEPES
buffer (pH 7.4)) and cooled slowly from
˚C 90
to 4˚C. The
annealed oligonucleotides were ligated into the BglII and HindIII
sites of the retroviral vector pSuper.retro.neo+GFP (pSRNG)
according to the manufacturer’s protocol (Oligoengine). A noncatalytic ribozyme targeted to the same sequence was created by
an A to G mutation in the catalytic core. This oligonucleotide was
synthesized and similarly cloned into pSRNG.
Ligation was carried out using T4 DNA Ligase
(Promega) in a 4ºC overnight reaction. The ligated plasmids were
transformed into JM109 cells and the resulting colonies were
screened for the presence of the ribozyme. For this, miniprep
DNA was screened by PCR using a plasmid-specific primer pair
that framed the cloning site. The PCR reaction consisted of 100
pMol of each primer and 2X PCR Master Mix (50units/mL Taq
DNA Polymerase) (Promega). Positive clones were indicated by
the presence of a 482 bp fragment. Correct ribozyme insertion
into the resulting plasmids, pSRNG5910 and pSRNG5910∆, was
verified by sequencing.

Cell lines and transfections
293T and NIH-3T3 cells were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% Fetal Bovine Serum (FBS) in a humidified 37°C
incubator with 5% CO 2 . All transfections were done by calcium
phosphate precipitation based on the method of Berkner and
Sharp (15). Briefly, 293T cells were plated to 50-70% confluency
onto 60 mm dishes 24 hours prior to transfection. The cells were
transiently transfected with 4 µg of plasmid DNA in 125 mM
CaCl 2 , and 2X HBS (280 mM NaCl/ 1.5 mM Na 2 HPO 4 / 50 mM
HEPES Buffer (pH 7.05)). The resulting precipitate was added to
the culture medium and allowed to be taken up by the cells.
Transfection efficiency, as measured by GFP (pLNCE and
pSRNG5910) or β-galactosidase (pLNCLZRz) expression was
analyzed as a function of transfection time. For this, 293T cells
were allowed to remain in contact with the DNA precipitate for 4,
8, 12, or 24 hours. Transgene expression was assayed 24 hours
after removal of the DNA precipitate.
GFP expression was analyzed directly using an
Olympus CKX41 inverted microscope with epifluorescence. βgalactosidase expression was measured by the ability to
metabolize X-gal (10) For this, cells were washed twice with PBS
and fixed for 15 minutes with 0.1 M Sodium Phosphate, pH 7.0/1
mM MgCl 2/ 0.25% glutaraldehyde. Subsequently, the cells were
washed three times with PBS, and stained by the addition of Xgal (PBS/4 mM K 4 Fe(CN) 6 .3H 2 O/4 mM K 3 Fe(CN) 6 ,/10 mM
MgCl 2 /0.03% X-gal). The presence of blue-stained cells after 24
hours indicated positive transfection.
Recombinant Virus Production
Recombinant viruses were produced in 293T cells
using a transient two-plasmid system consisting of a retroviral
vector and a helper plasmid (10;14). Three retroviruses were
analyzed for their ability to generate retroviruses in this system:
pSRNG5910∆, pLNCE, and pLNCLzRz. All are Mo-MLV
viruses that express either GFP (pSRNG5910∆, pLNCE) or βgalactosidase (pLNCLzRz). pPAM3 is a Mo-MLV based helper
plasmid that expresses all retroviral structural genes, including an
amphotropic glycoprotein (16).
To generate recombinant retrovirus particles for
transduction into target cells, 0.5 x 106 293T cells were plated
onto 60mm dishes. After 24 hours, these cells were transfected as
described using 4 µg helper plasmid (pPAM3) and 4 µg retroviral
vector (pSRNG5910∆, pLNCE, or pLNCLZRz). The resulting
precipitate was allowed to be taken up by the cells from 4 to 24
hours, after which time the medium was replaced. Twenty-four
hours later, the virus-containing medium was harvested from the
producer cells, filtered through a 0.45 µm syringe filter, and
stored at -80ºC.
The presence of virus particles in the harvested medium
was determined following transduction of target cells. For this,
0.25 x 106 NIH-3T3 cells were plated onto 35mm dishes. After
24 hours, these cells were transduced by the addition of one
milliliter each of harvested medium and fresh culture medium
containing 8 µg polybrene (4 µg/ml). The cells and virus particles
were incubated together for 24 hours, after which the medium
was replaced. After an additional 24 hours, virus titer was
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determined from the number of GFP or X-gal positive cells.
Virus titer was determined from the average number of positive
target cells in 10-20 randomly chosen fields at 200X using brightfield or epifluorescence microscopy. This number was
extrapolated to determine the total number of positive cells.
Optimizing virus titer
Transfection incubation time, referring to the length of
time the transfection reagent remained on producer cells, was
altered to optimize virus titer. 293T cells were incubated with
DNA precipitate at four different time points: 4, 8, 12, and 24
hours. After each time point, the medium was replaced and the
cells incubated for an additional 24 hours. The virus containing
medium was harvested and used to transduce NIH-3T3 cells as
described. GFP or β-galactosidase expression was monitored, and
virus titer was determined.

Results
The HIV-1 NL43 genomic sequence was analyzed for
the presence of potential hammerhead ribozyme target sites. One
site, a pGUA located at nucleotide 5910 was used to design an
anti-tat hammerhead ribozyme. This ribozyme and its noncatalytic control (Figure 1) were synthesized and cloned into the
retroviral vector, pSuper.retro.neo+GFP. Sequencing was used to
verify the ribozyme sequence in each of the resulting plasmids:
pSRNG5910 and pSRNG5910∆ (Figure 2). Once cloned,

Figure 3. GFP expression. 293T cells were transfected with
pSRNG5910∆ by calcium phosphate precipitation. GFP expression was
monitored 48 hours later.

The ability to generate recombinant retroviral particles
in a transient transfection system was next investigated using a
retroviral vector (pSRNG5910∆, pLNCE, or pLNCLZRz) and a
helper plasmid (pPAM3) to produce viral particles in 293T cells.
Forty-eight hours after transfection, the virus-containing medium
was harvested and used to transduce NIH-3T3 cells. The producer
and target cells were analyzed for either GFP or β-galactosidase
expression (Figure 4) as a measure of transfection (293T cells) or
transduction (NIH-3T3 cells). In these tests, virus production was
observed using both pLNCE and pLNCLZRz. However virus
production using the pSRNG5910D vector was not observed in
this series of experiments (Figure 4).

pLNCE

Figure 2. Retroviral vector pSRNG5910. Tat5910 oligonucleotides were
synthesized and cloned into the BglII and HindIII sites of
pSuper.retro.neo+GFP. The resulting vector is shown. A similar vector,
pSRND5910∆, was created by cloning the non-catalytic version of the
ribozyme.

pSRNG5910∆ was tested to ensure GFP expression was not
affected by the cloning process. 293T cells were transiently
transfected using the calcium phosphate method and after 48
hours analyzed for transgene expression. These results indicated
relatively high levels of GFP expression (Figure 3). However,
GFP levels were noticeably lower than in cells transfected in
parallel with pLNCE (data not shown).

pLNCLZRz

pSRNG5910∆

Figure 4. Production of recombinant retrovirus. 293T cells were
transiently transfected with pPAM3 and one of three retroviral vectors.
Transfection efficiency was determined by the relative number of GFP- or
X-gal positive cells (Upper panels). Virus containing medium was
harvested and used to transduce NIH-3T3 cells. Virus-mediated
expression was only evident in pLNCE and pLNCLZRz transduced cells
(Lower panels). GFP-positive cells are green. X-gal positive cells are
blue.

To optimize virus titer, the length of transfection
incubation period, as measured by the time the DNA precipitate
was incubated with the 293T cells, was altered. For this, the
transfection reagent was left on the 293T cells for 4, 8, 12, or 24
hours. The precipitate was removed by a change of medium and
24 hours later, virus was harvested in the culture medium. At this
time the 293T producer cells were analyzed for GFP or βgalactosidase expression to make sure the transfection was
successful. Regardless of the transfection incubation period, all
293T transfection experiments yielded positive GFP or βgalactosidase expression. For the retroviral vector pSRNG5910∆,
higher GFP expression was observed in the 12 hour incubation
period compared to the four and eight hour periods. However, no
visible differences were evident in GFP expression among the 12
and 24 hour incubation periods (data not shown).
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The ultimate purpose of these transfection studies was
to determine if virus production was increased by allowing the
293T producer cells to remain in contact with the transfection
reagents for longer periods of time. To determine the virus titer
produced in these experiments, NIH-3T3 cells were incubated
with virus-containing medium harvested from the producer cells.
With regards to virus production, extremely low levels of GFP
expression was observed in the NIH-3T3 cells transduced with
the harvested medium from producer cells transfected with
pPAM3 and pSRNG5910∆. This was true of all incubation
periods, and resulted in an inability to determine a reliable titer
for this vector (Figure 4). On the other hand, with the exception
of the eight hour incubation period, recombinant virus was
produced in target cells transduced with pLNCE or pLNCLZRz,
as measured by the number of GFP or X-gal positive cells (Figure
5). Analysis of virus titer generated by pLNCLZRz transfections
for all incubation periods indicated an increase over time. The
maximum titer obtained with this vector was measured at the 24
hour time point as 1 x 104 virus particles per milliliter (Figure 5).
The virus titer produced using pLNCE indicated a large increase
at the 12 hour time point; however, the titer at the 24 hour time
point was approximately 50% less (Figure 5). At all time points
tested, the pSRNG5910D vector failed to produce a measurable
titer.
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Figure 5. Optimization of virus titer. The number of virus particles per
milliliter of harvested culture medium was determined for pLNCE and
pLNCLZRz transduced NIH-3T3 cells. Virus titer was optimized by
increasing the transfection incubation tome from 4 to 24 hours. Virus titer
was found to be directly related to this increase.

Conclusions
Previous studies have shown that hammerhead
ribozymes targeted to HIV-1 accessory genes such as tat can
down regulate virus replication. Many of these studies have used
retroviral vectors to express ribozymes as part of an RNA
Polymerase II transcript (10;11). While effective, these
transcripts are often large and likely produce secondary structures
that may interfere with efficient ribozyme cleavage. The pSUPER
family of vectors were specifically created to express siRNAs
from the RNA Polymerase I H1 promoter and should represent a
good choice to express hammerhead ribozymes. Additionally, the

pSUPER retroviral vectors are self-inactivating and express
neomycin phosphotransferase and GFP from the PGK promoter.
The primary goal of this project was to clone a
hammerhead ribozyme targeted to HIV-1 tat into pSRNG and to
characterize the resulting vector prior to its use in anti-HIV
experiments. A second goal was to determine the optimal
conditions to produce recombinant retrovirus particles in a
transient two-plasmid system. The resulting plasmids,
pSRNG5910 and pSRNG5910∆ were generated for this purpose.
Initial tests indicated that both retroviral vectors expressed GFP
when transiently transfected into 293T cells. However, in all
cases the non-pSUPER retrovirus, pLNCE, generated greater
GFP expression than either pSRNG5910 or pSRNG5910∆ in
transfected 293T cells. Although it does not explain the overall
lower transfection efficiency of pSRNG5910∆, it is likely that
pLNCE generated greater levels of GFP expression due to
transcriptional control of the immediate early CMV promoter. In
comparison, GFP expression in the pSUPER vector is controlled
by the comparatively weaker PGK promoter. In fact, a number of
cells transfected with pSRNG5910∆ appeared to be very weakly
positive for GFP expression, although they were not counted as
GFP-positive for these studies. The other retrovial vector used in
these experiments, pLNCLZRz also yielded higher numbers of
transfected cells, and like pLNCE, this plasmid possesses a CMV
promoter that controls expression of β-galactosidase.
The use of these plasmids as retroviral vectors was next
studied by comparing the ability of pSRNG5910∆ to produce
virus with the retroviral vectors pLNCE and pLNCLZRz. In these
studies, pSRNG5910∆ failed to produce measurable virus.
Although a very small number of GFP-positive target cells were
identified, the number was too small to determine a reliable titer.
Subsequently, the length of transfection incubation period was
altered in an attempt to optimize virus titer. Transfection with the
helper plasmid, pPAM3, and either pLNCE or pLNCLZRz
produced measurable virus titers, up to a high of 104 particles per
milliliter. Again, pSRNG5910∆ failed to produce measurable
virus titers in these experiments. Overall; however, these result
did indicate that our two-plasmid system successfully generated
recombinant virus.
It is quite possible that the two different ways virus
expression was measured and used to determine titer played a
role in the discrepancies seen in the virus titer optimization
experiments (Figure 5). Target cells transduced with recombinant
virus produced using the pLNCLZRz vector resulted in the ability
to metabolize X-gal.; therefore staining produced blue cells that
were easy to identify and count using brightfield microscopy.
There is a higher degree of uncertainty involved in scoring GFPpositive cells produced from transduction with recombinant virus
from pLNCE and pSRNG5910∆. It may be that when using these
vectors, a more reliable way of determining titer would be to
generate neomycin resistant colonies.
Ultimately, because pSRNG5910∆ failed to generate
measurable levels of recombinant virus, optimization studies will
be impractical until a method for producing virus with this vector
can be developed. Although transient systems may be
successfully used to generate virus using pSRNG-based vectors,
future studies will need to increase transfection efficiency. One
such method may be through the use of lipid-based transfection
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procedures. Alternatively, it may be necessary to generate a stable
producer line for efficient virus production.
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